Key facts
- It has raised $3.4M; the latest was Later Stage VC ($3.4M) in Nov 2025.
- Notable investors include North 50 Venture Capital, Altamira (Warsaw), Hard2beat, Medical Research Agency, iif.vc.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pikralida
- ·The full record, as it builds
Funding rounds
No funding rounds for Pikralida are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pikralida
Operator of a biopharmaceutical start-up intended to develop medicinal products to address unmet medical needs with efficacy and safety in pharmacotherapy. The company's project covers therapeutic solutions based on innovative small-molecule drugs, innovative combinations of drug formulations, as well as state-of-the-art drug delivery systems, enabling pharmaceutical companies to get products for the patients suffering from civilisation and neurological diseases and those from the geriatric population.
- Sector
- Healthcare
- HQ
- Poznań, Poland
- Founded
- 2019
- Employees
- 20
- Website
- pikralida.eu/
- Ownership
- Privately Held (backing)
Pikralida doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pikralida shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pikralida in its N-PORT filings yet. We sweep new filings monthly.